ĶªÌ¡G¾H¥ò¤¯
¤@¡B ¬ã¨sI´º
¥»¬ã¨sªº¥Øªº¦b±´°Q¡A¿©±wÂಾ©Ê¨ÅÀùªº¯f±w¨Ï¥Îtrastuzumab¬°¥DªºªvÀøp¹º®É¡A¯f¤H¦å²MªºHer-2/neu²ÓM¥~¤ù¬q(extracellular
domain, ECD)¿@«×ªº¦´ÁÅܤơA¬O§_¯à°÷¹w´ú¯f¤HªºÁ{§É¯e¯f¶i®i¡C
¤G¡B ¬ã¨s¹ï¶H
¦³55¦ì¿©±wÂಾ©Ê¨ÅÀùªº¯f±w¡A¦o̧¡¦³Her-2/neuªº¹L«×ªí²{(Her-2/neu-overexpressing)¡C¦b¨C¶gµ¹¤©trastuzumabªvÀø«e¡A¥ý¦¬¶°¦o̪º¦å²M¡A¨Ã¨Ï¥ÎELISA¤èªk´ú©wHer-2/neu¿@«×¡C¦b³sÄòªºªvÀø´Á¶¡°µ¿@«×ªººÊ±±¡Aµû¦ô³sÄò©ÊºÊ±±¬O§_¯à°µ¬°¯e¯f¶i®iªº«ü¼Ð¡C
¤T¡B ¬ã¨sµ²ªG
Y¯f±w¦bªvÀø«eªºHer-2/neu²ÓM¥~¤ù¬q(ECD)¿@«×¸û°ª¡]„d 15 ng/mL¡^¡A«h¨äªvÀø¤ÏÀ³²v¦³©úÅã¸û°ª¡]35% vs. 7%¡ApÈ¡×0.045¡^¡F¦ý¡uµL¯e¯f¶i®i¦s¬¡´Á(progression-free
survival)¡v¤Î¡uÁ`¦s¬¡´Á(overall survival)¡v¦bHer-2/neu²ÓM¥~¤ù¬q(ECD)¿@«×¥¿±`¤Î¸û°ªªº¯f±w¤§¶¡¡A«hµL©úÅã®t²§¡C
Y¯f±w¹ïªvÀø¦³¤ÏÀ³¡AHer-2/neu²ÓM¥~¤ù¬q(ECD)¿@«×¦bªvÀø°_©lªº²Ä8¤Ñ¡A´N·|¦³·N¸q¦a¤U°¡]¨C¶g´ú±oªº¿@«×»Pbaseline¬Û¤ñ¸û¡A©Ò¦³ªºpȧ¡¡Õ0.001¡^¡C¬Û¹ï¦a¡A¦b¯e¯f¤´¶i®iªº¯f±w¤¤¡A¨äHer-2/neu²ÓM¥~¤ù¬q(ECD)¿@«×«h¨S¦³©úÅã§ïÅÜ¡C
¦hÅܼÆÅÞ¿è°jÂk¤ÀªR(multiple logistic regression analyses)Åã¥Ü¡A¦b¨Ï¥Îtrastuzumab¬°¥DªºªvÀøp¹º®É¡A¦bªvÀø²Ä8¤Ñ¥H«á¡AHer-2/neu²ÓM¥~¤ù¬q(ECD)¿@«×´î¤Öªº¡u°ÊºAÅܤÆ(kinetics)¡v¥i¥Î©ó·Ç½T¹w´úªvÀø¤ÏÀ³²vªº°ß¤@¦]¤l¡]pÈ¡×0.020¡^¡C¦¹¥~¡AHer-2/neu²ÓM¥~¤ù¬q(ECD)¿@«×¼W¥[ªº³sÄò©Ê©w¶q¡A¥i¦bªvÀøªº²Ä15¤Ñ®É§Y¥i¹w´ú¯e¯f®iªºrisk¡]pÈ¡×0.010¡^¡C
¥|¡B µ²½×
Her-2/neu²ÓM¥~¤ù¬q(ECD)¿@«×ªº³sÄò©ÊºÊ´ú(serial monitoring)À³¥i°µ¬°¤@¶µ¦³¥Îªº¤u¨ã¡AÀ³¥Î¦b¨Ï¥Îtrastuzumab¬°¥DªºªvÀøp¹º®É¡A¥i¥Î¨Ó¦´Á¹w´úªvÀø¤ÏÀ³¡BµL¯e¯f¶i®i¦s¬¡´Á(progression-free
survival)¡A¦Ó§ó¯à±NªvÀø¤è¦¡»P¸ê·½°µ¾A·íªº¦w±Æ¡C